X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

X4 Pharmaceuticals reports positive trial results and financial resilience

X4 Pharmaceuticals showcased strong clinical performance with positive trial results for mavorixafor, while also strengthening its financial position despite reporting a net loss.
The company faces challenges in managing R&D expenses and addressing ongoing financial losses, but opportunities lie in market expansion and regulatory progress for mavorixafor.
By navigating challenges effectively and capitalizing on opportunities, X4 Pharmaceuticals can position itself for growth and success in advancing its lead candidate to market.
Investor interest, regulatory milestones, and strategic partnerships will play key roles in shaping X4 Pharmaceuticals' future trajectory and market competitiveness.

X4 Pharmaceuticals reports successful Phase III trial and plans FDA filing

X4 Pharmaceuticals demonstrated significant progress with mavorixafor and plans for regulatory filings, supported by a healthy cash position.
While facing challenges in managing expenses and achieving profitability, the company remains focused on advancing its pipeline and engaging with stakeholders.
Opportunities lie in upcoming events for collaboration and data dissemination, signaling potential growth avenues for X4 Pharmaceuticals.
Overall, X4 Pharmaceuticals' Q1 2023 earnings call highlighted achievements, financial standing, challenges, and future prospects for investors and stakeholders.

X4 Pharmaceuticals reports strong Q2 results and advances mavorixafor trials

X4 Pharmaceuticals showcased positive trial results and financial strength, positioning the company for future growth and market success.
While facing challenges in upcoming trials and commercialization, the company's strategic leadership and product potential offer opportunities for expansion.
Navigating regulatory processes and market dynamics will be key to realizing the full potential of mavorixafor and driving long-term value for stakeholders.
Overall, X4 Pharmaceuticals' focus on innovation, strategic partnerships, and market insights bode well for their competitive positioning and growth trajectory.

X4 Pharmaceuticals poised for mavorixafor launch in 2024

X4 Pharmaceuticals is on track for a significant mavorixafor launch in 2024, backed by strong financials and strategic initiatives. Challenges in patient diagnosis and access require focused efforts post-approval.

X4 Pharmaceuticals reports milestone achievements and financial stability for growth

X4 Pharmaceuticals showcased strong clinical advancements and financial stability in 2023, positioning them for potential FDA approval and market expansion.
While facing challenges in managing expenses and addressing stakeholder queries, the company remains optimistic about revenue opportunities and growth prospects.
With a focus on regulatory milestones, market entry strategies, and revenue generation, X4 Pharmaceuticals aims to capitalize on the momentum from their achievements.

X4 Pharmaceuticals reports FDA approval for XOLREMDI, faces financial challenges

X4 Pharmaceuticals faces financial challenges with a significant net loss despite having a substantial cash position.
The FDA approval of XOLREMDI for WHIM syndrome highlights the company's progress in drug development.
Opportunities lie in expanding XOLREMDI's market reach, monetizing PRV, and advancing R&D efforts for future growth.

X4 Pharmaceuticals excels in Phase II study and FDA approval, eyes market expansion in 2025

X4 Pharmaceuticals showcased positive results from the Phase II study of mavorixafor and FDA approval for XOLREMDI, signaling significant advancements in product development and market penetration.
While challenges exist in transitioning to Phase III trials and ensuring successful commercialization, the company's focus on physician comfort, disease awareness, and patient education presents opportunities for growth.
Overall, X4 Pharmaceuticals is well-positioned to capitalize on its recent achievements and drive further success through strategic initiatives in product development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. Its clinical candidate is mavorixafor. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced the appointment of Art Taveras, Ph.D., as Chief Scientific Officer. Dr. Taveras will lead all research and non-clinical development functions supporting the company's pipeline of investigational therapies.

X4 Pharmaceuticals Appoints Art Taveras, Ph.D., as Chief Scientific Officer

BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the third quarter ended September 30, 2020, and provide an update on recent business highlights, on November 5, 2020.

X4 Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020

BOSTON, Oct. 08, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead asset, mavorixafor, for the treatment of adult patients with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene.

X4 Pharmaceuticals Announces Fast Track Designation Granted by the FDA to Mavorixafor for the Treatment of WHIM Syndrome

BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced the expansion of its board of directors with the appointment of Alison Lawton, a biopharmaceutical industry veteran with more than 30 years of experience in a wide range of senior executive and operational roles.

X4 Pharmaceuticals Expands Board of Directors Through Appointment of Biopharmaceutical Industry Veteran Alison Lawton

CAMBRIDGE, Mass., Sept.  03, 2020  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that its management team will participate in the following September virtual investor conferences: Citi 15th Annual BioPharma Conference, Cantor Fitzgerald Virtual Global Healthcare Conference and Oppenheimer & Co. Fall Healthcare Life Sciences & MedTech Summit.

X4 Pharmaceuticals to Participate in Three September Virtual Investor Conferences

Manuscript further details positive clinical results and long-term tolerability of mavorixafor in ongoing Phase 2 study

X4 Pharmaceuticals Announces Publication of Mavorixafor Phase 2 Clinical Data for Treatment of WHIM Syndrome in ‘Blood’ - the Official Journal of the American Society of Hematology

CAMBRIDGE, Mass., Aug.  10, 2020  (GLOBE NEWSWIRE) --  X4 Pharmaceuticals, Inc.  (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present and conduct one-on-one meetings during the Virtual Canaccord Genuity 40th Annual Growth Conference on Wednesday, August 12th, 2020 at 2:30 pm Eastern Time.

X4 Pharmaceuticals to Present and Participate in the Canaccord Genuity’s 40th Annual Growth Conference

X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q2 2020 Results - Earnings Call Transcript

Presentation of positive clinical data at EHA 2020 supporting the ongoing Phase 3 trial in WHIM syndrome

X4 Pharmaceuticals Reports Second Quarter 2020 Financial Results  and Provides Corporate Update

CAMBRIDGE, Mass., July  16, 2020  (GLOBE NEWSWIRE) --  X4 Pharmaceuticals, Inc.  (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the second quarter ended June 30, 2020, and provide an update on recent business highlights, on July 30, 2020.

X4 Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on July 30, 2020

Sustained efficacy and safety trends observed for up to 28.6 months    support ongoing pivotal Phase 3 trial dosing and endpoints, including selection of the measurement of time above threshold for absolute neutrophil count as primary endpoint

X4 Pharmaceuticals Presents Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome at EHA 2020

CAMBRIDGE, Mass., June  11, 2020  (GLOBE NEWSWIRE) --  X4 Pharmaceuticals, Inc.  (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced the promotion of Renato Skerlj, Ph.D., to the position of Chief Scientific Officer. Dr. Skerlj is one of the scientific founders of X4 and co-inventor of X4’s lead drug candidate, mavorixafor. He joined the company in September 2019 as Senior Vice President, Research and Development. As Chief Scientific Officer, Dr. Skerlj will lead all research and development functions and pre-clinical development activities.

X4 Pharmaceuticals Promotes Renato Skerlj, Ph.D., to Chief Scientific Officer

B2Gold

Constellium NV Class A

Dynavax Technologies

Identiv

LiveXLive Media

Ovid Therapeutics

Plug Power

Sequans Communications

Vonage Hlds

For new investors, stocks under $10 offer both learning opportunities and huge upside potential. Here are 10 names to buy cheap.

10 Cheap Stocks to Buy Under $10

CAMBRIDGE, Mass., June  01, 2020  (GLOBE NEWSWIRE) --  X4 Pharmaceuticals, Inc.  (Nasdaq:  XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that, on May 29, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 55,200 shares of X4’s common stock and were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4).

X4 Pharmaceuticals  Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arsanis Inc (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Arsanis Inc (XFOR) Moves to Buy: Rationale Behind the Upgrade

X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q1 2020 Results - Earnings Call Transcript

X4 Pharmaceuticals, Inc. (C) CEO Paula Ragan on Q4 2019 Results - Earnings Call Transcript

Avid Bioservices

Endo International

IGM Biosciences Inc

Illumina

IVERIC bio Inc

Kodiak Sciences Inc

Mylan

Neovasc

Pacira Pharmaceuticals

Pfizer

After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in their portfolio.

News for X4 Pharmaceuticals Inc Stock (XFOR)